Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Väänänen HK[au]:

Estrogen and bone metabolism. Väänänen HK et al. Maturitas. (1996)

The cell biology of osteoclast function. Väänänen HK et al. J Cell Sci. (2000)

Role of fibroblast growth factor receptors (FGFR) and FGFR like-1 (FGFRL1) in mesenchymal stromal cell differentiation to osteoblasts and adipocytes. Kähkönen TE et al. Mol Cell Endocrinol. (2018)

Search results

Items: 1 to 50 of 198

1.

Alendronate-induced disruption of actin cytoskeleton and inhibition of migration/invasion are associated with cofilin downregulation in PC-3 prostate cancer cells.

Virtanen SS, Ishizu T, Sandholm JA, Löyttyniemi E, Väänänen HK, Tuomela JM, Härkönen PL.

Oncotarget. 2018 Aug 24;9(66):32593-32608. doi: 10.18632/oncotarget.25961. eCollection 2018 Aug 24.

2.

Role of fibroblast growth factor receptors (FGFR) and FGFR like-1 (FGFRL1) in mesenchymal stromal cell differentiation to osteoblasts and adipocytes.

Kähkönen TE, Ivaska KK, Jiang M, Büki KG, Väänänen HK, Härkönen PL.

Mol Cell Endocrinol. 2018 Feb 5;461:194-204. doi: 10.1016/j.mce.2017.09.015. Epub 2017 Sep 18.

PMID:
28923346
3.

The effects of acute hyperinsulinemia on bone metabolism.

Ivaska KK, Heliövaara MK, Ebeling P, Bucci M, Huovinen V, Väänänen HK, Nuutila P, Koistinen HA.

Endocr Connect. 2015 Sep;4(3):155-62. doi: 10.1530/EC-15-0022. Epub 2015 Jun 5.

4.

Novel perspectives on the transcytotic route in osteoclasts.

Hirvonen MJ, Fagerlund K, Lakkakorpi P, Väänänen HK, Mulari MT.

Bonekey Rep. 2013 Mar 13;2:306. doi: 10.1038/bonekey.2013.40. eCollection 2013.

5.

Serum osteocalcin is not associated with glucose but is inversely associated with leptin across generations of nondiabetic women.

Lu C, Ivaska KK, Alen M, Wang Q, Törmäkangas T, Xu L, Wiklund P, Mikkola TM, Pekkala S, Tian H, Väänänen HK, Cheng S.

J Clin Endocrinol Metab. 2012 Nov;97(11):4106-14. doi: 10.1210/jc.2012-2045. Epub 2012 Sep 4.

PMID:
22948754
6.

Rab13 is upregulated during osteoclast differentiation and associates with small vesicles revealing polarized distribution in resorbing cells.

Hirvonen MJ, Mulari MT, Büki KG, Vihko P, Härkönen PL, Väänänen HK.

J Histochem Cytochem. 2012 Jul;60(7):537-49. doi: 10.1369/0022155412448069. Epub 2012 May 4.

7.

Transient 100 nM dexamethasone treatment reduces inter- and intraindividual variations in osteoblastic differentiation of bone marrow-derived human mesenchymal stem cells.

Alm JJ, Heino TJ, Hentunen TA, Väänänen HK, Aro HT.

Tissue Eng Part C Methods. 2012 Sep;18(9):658-66. doi: 10.1089/ten.TEC.2011.0675. Epub 2012 May 14.

PMID:
22428545
8.

Urinary osteocalcin and serum pro-C-type natriuretic peptide predict linear catch-up growth in infants.

Kilpeläinen L, Ivaska KK, Kuiri-Hänninen T, Väänänen HK, Rehfeld JF, Goetze JP, Sankilampi U, Dunkel L.

J Bone Miner Res. 2012 Jul;27(7):1528-35. doi: 10.1002/jbmr.1596.

9.

The effect of oral glucose tolerance test on serum osteocalcin and bone turnover markers in young adults.

Paldánius PM, Ivaska KK, Hovi P, Andersson S, Väänänen HK, Kajantie E, Mäkitie O.

Calcif Tissue Int. 2012 Feb;90(2):90-5. doi: 10.1007/s00223-011-9551-8. Epub 2011 Dec 8.

PMID:
22147278
10.

Receptor tyrosine kinase inhibition causes simultaneous bone loss and excess bone formation within growing bone in rats.

Nurmio M, Joki H, Kallio J, Määttä JA, Väänänen HK, Toppari J, Jahnukainen K, Laitala-Leinonen T.

Toxicol Appl Pharmacol. 2011 Aug 1;254(3):267-79. doi: 10.1016/j.taap.2011.04.019. Epub 2011 May 4.

PMID:
21586300
11.

The critical role of IL-34 in osteoclastogenesis.

Chen Z, Buki K, Vääräniemi J, Gu G, Väänänen HK.

PLoS One. 2011 Apr 8;6(4):e18689. doi: 10.1371/journal.pone.0018689.

12.

A rationale for osteoclast selectivity of inhibiting the lysosomal V-ATPase a3 isoform.

Nyman JK, Väänänen HK.

Calcif Tissue Int. 2010 Sep;87(3):273-83. doi: 10.1007/s00223-010-9395-7. Epub 2010 Jul 2.

PMID:
20596699
13.

Degradation of hydroxyapatite in vivo and in vitro requires osteoclastic sodium-bicarbonate co-transporter NBCn1.

Riihonen R, Nielsen S, Väänänen HK, Laitala-Leinonen T, Kwon TH.

Matrix Biol. 2010 May;29(4):287-94. doi: 10.1016/j.matbio.2010.01.003. Epub 2010 Jan 15.

PMID:
20079835
14.

Bone turnover markers and prediction of fracture: a prospective follow-up study of 1040 elderly women for a mean of 9 years.

Ivaska KK, Gerdhem P, Väänänen HK, Akesson K, Obrant KJ.

J Bone Miner Res. 2010 Feb;25(2):393-403. doi: 10.1359/jbmr.091006.

15.

Overexpression of vascular endothelial growth factor C increases growth and alters the metastatic pattern of orthotopic PC-3 prostate tumors.

Tuomela J, Valta M, Seppänen J, Tarkkonen K, Väänänen HK, Härkönen P.

BMC Cancer. 2009 Oct 12;9:362. doi: 10.1186/1471-2407-9-362.

16.

Evidence for the role of osteocytes in the initiation of targeted remodeling.

Heino TJ, Kurata K, Higaki H, Väänänen HK.

Technol Health Care. 2009;17(1):49-56. doi: 10.3233/THC-2009-0534.

PMID:
19478405
17.

Osteocyte-derived HB-GAM (pleiotrophin) is associated with bone formation and mechanical loading.

Imai S, Heino TJ, Hienola A, Kurata K, Büki K, Matsusue Y, Väänänen HK, Rauvala H.

Bone. 2009 May;44(5):785-94. doi: 10.1016/j.bone.2009.01.004. Epub 2009 Jan 15.

PMID:
19442624
18.

FGF-8b induces growth and rich vascularization in an orthotopic PC-3 model of prostate cancer.

Valta MP, Tuomela J, Vuorikoski H, Loponen N, Väänänen RM, Pettersson K, Väänänen HK, Härkönen PL.

J Cell Biochem. 2009 Jul 1;107(4):769-84. doi: 10.1002/jcb.22175.

PMID:
19415685
19.

Effect of impact exercise on bone metabolism.

Vainionpää A, Korpelainen R, Väänänen HK, Haapalahti J, Jämsä T, Leppäluoto J.

Osteoporos Int. 2009 Oct;20(10):1725-33. doi: 10.1007/s00198-009-0881-6. Epub 2009 Mar 5.

PMID:
19262975
20.

Overexpression of cathepsin K accelerates the resorption cycle and osteoblast differentiation in vitro.

Morko J, Kiviranta R, Mulari MT, Ivaska KK, Väänänen HK, Vuorio E, Laitala-Leinonen T.

Bone. 2009 Apr;44(4):717-28. doi: 10.1016/j.bone.2008.11.019. Epub 2008 Dec 11.

PMID:
19118660
21.

Can elevated serum TRACP-5b levels predict stress fractures? A cohort study.

Ruohola JP, Mulari M, Haataja RI, Väänänen HK, Pihlajamäki HK.

Scand J Surg. 2009;98(4):239-43.

PMID:
20218422
22.

Clinical performance of six different serum tartrate-resistant acid phosphatase assays for monitoring alendronate treatment.

Fagerlund KM, Janckila AJ, Ylipahkala H, Tiitinen SL, Nenonen A, Cheng S, Uusi-Rasi K, Yam LT, Väänänen HK, Halleen JM.

Clin Lab. 2008;54(9-10):347-54.

PMID:
19097492
23.

Improved methods for testing antiresorptive compounds in human osteoclast cultures.

Rissanen JP, Ylipahkala H, Fagerlund KM, Long C, Väänänen HK, Halleen JM.

J Bone Miner Metab. 2009;27(1):105-9. doi: 10.1007/s00774-008-0002-1. Epub 2008 Nov 19.

PMID:
19018457
24.

Analysis by siRNA_profile program displays novel thermodynamic characteristics of highly functional siRNA molecules.

Muhonen P, Parthasarathy RN, Janckila AJ, Büki KG, Väänänen HK.

Source Code Biol Med. 2008 May 21;3:8. doi: 10.1186/1751-0473-3-8.

25.

Serial assessment of serum bone metabolism markers identifies women with the highest rate of bone loss and osteoporosis risk.

Ivaska KK, Lenora J, Gerdhem P, Akesson K, Väänänen HK, Obrant KJ.

J Clin Endocrinol Metab. 2008 Jul;93(7):2622-32. doi: 10.1210/jc.2007-1508. Epub 2008 May 6.

PMID:
18460567
26.

Estrogen and the selective estrogen receptor modulator (SERM) protection against cell death in estrogen receptor alpha and beta expressing U2OS cells.

Kallio A, Guo T, Lamminen E, Seppänen J, Kangas L, Väänänen HK, Härkönen P.

Mol Cell Endocrinol. 2008 Jul 16;289(1-2):38-48. doi: 10.1016/j.mce.2008.03.005. Epub 2008 Mar 25.

PMID:
18455292
27.

Osteoclast lineage and function.

Väänänen HK, Laitala-Leinonen T.

Arch Biochem Biophys. 2008 May 15;473(2):132-8. doi: 10.1016/j.abb.2008.03.037. Epub 2008 Apr 6. Review.

PMID:
18424258
28.

Recombinant VSV G proteins reveal a novel raft-dependent endocytic pathway in resorbing osteoclasts.

Mulari MT, Nars M, Laitala-Leinonen T, Kaisto T, Metsikkö K, Sun Y, Väänänen HK.

Exp Cell Res. 2008 May 1;314(8):1641-51. doi: 10.1016/j.yexcr.2008.02.011. Epub 2008 Mar 4.

PMID:
18387607
29.

FGF-8 is involved in bone metastasis of prostate cancer.

Valta MP, Tuomela J, Bjartell A, Valve E, Väänänen HK, Härkönen P.

Int J Cancer. 2008 Jul 1;123(1):22-31. doi: 10.1002/ijc.23422.

30.

Overexpression of human hydroxysteroid (17beta) dehydrogenase 2 induces disturbance in skeletal development in young male mice.

Shen Z, Peng Z, Sun Y, Väänänen HK, Poutanen M.

J Bone Miner Res. 2008 Aug;23(8):1217-26. doi: 10.1359/jbmr.080322.

31.

Sequence and TLR9 independent increase of TRACP expression by antisense DNA and siRNA molecules.

Muhonen P, Avnet S, Parthasarathy RN, Janckila AJ, Halleen JM, Laitala-Leinonen T, Väänänen HK.

Biochem Biophys Res Commun. 2007 Aug 10;359(4):889-95. Epub 2007 Jun 6.

PMID:
17570345
32.

RNA interference tolerates 2'-fluoro modifications at the Argonaute2 cleavage site.

Muhonen P, Tennilä T, Azhayeva E, Parthasarathy RN, Janckila AJ, Väänänen HK, Azhayev A, Laitala-Leinonen T.

Chem Biodivers. 2007 May;4(5):858-73.

PMID:
17511001
33.

Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro.

Michael H, Härkönen PL, Kangas L, Väänänen HK, Hentunen TA.

Br J Pharmacol. 2007 Jun;151(3):384-95. Epub 2007 Apr 10.

34.

Membrane-bound carbonic anhydrases in osteoclasts.

Riihonen R, Supuran CT, Parkkila S, Pastorekova S, Väänänen HK, Laitala-Leinonen T.

Bone. 2007 Apr;40(4):1021-31. Epub 2006 Dec 22.

PMID:
17291844
35.

Monocyte-macrophage system as a target for estrogen and selective estrogen receptor modulators.

Härkönen PL, Väänänen HK.

Ann N Y Acad Sci. 2006 Nov;1089:218-27. Review.

PMID:
17261769
36.

Tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of bone resorption.

Halleen JM, Tiitinen SL, Ylipahkala H, Fagerlund KM, Väänänen HK.

Clin Lab. 2006;52(9-10):499-509. Review.

PMID:
17078477
37.

Associations between homocysteine, bone turnover, BMD, mortality, and fracture risk in elderly women.

Gerdhem P, Ivaska KK, Isaksson A, Pettersson K, Väänänen HK, Obrant KJ, Akesson K.

J Bone Miner Res. 2007 Jan;22(1):127-34.

38.

Serum TRACP 5b and ICTP as markers of bone metastases in breast cancer.

Korpela J, Tiitinen SL, Hiekkanen H, Halleen JM, Selander KS, Väänänen HK, Suominen P, Helenius H, Salminen E.

Anticancer Res. 2006 Jul-Aug;26(4B):3127-32.

39.

Effects of proteolysis and reduction on phosphatase and ROS-generating activity of human tartrate-resistant acid phosphatase.

Fagerlund KM, Ylipahkala H, Tiitinen SL, Janckila AJ, Hamilton S, Mäentausta O, Väänänen HK, Halleen JM.

Arch Biochem Biophys. 2006 May 15;449(1-2):1-7. Epub 2006 Mar 27.

PMID:
16620768
40.

Bone marrow cell differentiation induced by mechanically damaged osteocytes in 3D gel-embedded culture.

Kurata K, Heino TJ, Higaki H, Väänänen HK.

J Bone Miner Res. 2006 Apr;21(4):616-25. Epub 2006 Apr 5.

41.
42.

Regulation of osteoblast differentiation: a novel function for fibroblast growth factor 8.

Valta MP, Hentunen T, Qu Q, Valve EM, Harjula A, Seppänen JA, Väänänen HK, Härkönen PL.

Endocrinology. 2006 May;147(5):2171-82. Epub 2006 Jan 26.

PMID:
16439448
43.

Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover.

Nenonen A, Cheng S, Ivaska KK, Alatalo SL, Lehtimäki T, Schmidt-Gayk H, Uusi-Rasi K, Heinonen A, Kannus P, Sievänen H, Vuori I, Väänänen HK, Halleen JM.

J Bone Miner Res. 2005 Oct;20(10):1804-12.

44.

Cystatin B as an intracellular modulator of bone resorption.

Laitala-Leinonen T, Rinne R, Saukko P, Väänänen HK, Rinne A.

Matrix Biol. 2006 Apr;25(3):149-57.

PMID:
16321512
45.

Urinary osteocalcin is a useful marker for monitoring the effect of alendronate therapy.

Ivaska KK, Pettersson K, Nenonen A, Uusi-Rasi K, Heinonen A, Kannus P, Väänänen HK.

Clin Chem. 2005 Dec;51(12):2362-5. No abstract available.

46.

Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption.

Michael H, Härkönen PL, Väänänen HK, Hentunen TA.

J Bone Miner Res. 2005 Dec;20(12):2224-32. Epub 2005 Aug 1.

47.

Mesenchymal stem cells.

Väänänen HK.

Ann Med. 2005;37(7):469-79. Review.

PMID:
16278160
48.

Serum tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of skeletal changes in prostate cancer.

Salminen E, Ala-Houhala M, Korpela J, Varpula M, Tiitinen SL, Halleen JM, Väänänen HK.

Acta Oncol. 2005;44(7):742-7.

PMID:
16227166
49.

Isolated primary osteocytes express functional gap junctions in vitro.

Gu G, Nars M, Hentunen TA, Metsikkö K, Väänänen HK.

Cell Tissue Res. 2006 Feb;323(2):263-71. Epub 2005 Sep 21.

PMID:
16175387
50.

Inhibition of the osteoclast V-ATPase by small interfering RNAs.

Hu Y, Nyman J, Muhonen P, Väänänen HK, Laitala-Leinonen T.

FEBS Lett. 2005 Sep 12;579(22):4937-42.

Supplemental Content

Loading ...
Support Center